To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel to review Lilly's Olumiant

FDA's Arthritis Advisory Committee will meet on April 23 to discuss

Read the full 111 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE